Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …

Multiple myeloma (MM) remains an incurable hematological malignancy disease
characterized by the progressive dysfunction of the patient's immune system. In this context …

CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib,
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …

Simple Summary Macrophages are the “big eaters” of the immune system who are in charge
of engulfing undesirable substances. Macrophages are vital for the human body as they are …

Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months,
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …

Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …

Background The outcome of non-transplant eligible newly diagnosed multiple myeloma
(NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study …

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and
mortality. Despite advances in treatment, MM patients eventually experienced a relapse of …

Simple Summary The assessment of responses is critical in patients diagnosed with multiple
myeloma. Nowadays, one of the most informative parameters to discriminate responses to …